CREDENCE

The CREDENCE cardio-renal outcomes trial investigated the effect of canagliflozin on kidney and CV outcomes in patients with T2D and kidney disease. This module details the results.

CREDENCE
Rate this content
  • CREDENCE
  • CREDENCE
  • CREDENCE
  • CREDENCE: trial design1,2
  • CREDENCE included patients with T2D and established kidney disease
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go